Just caught wind of some pretty significant clinical trial results that biotech investors should probably pay attention to. Zenas BioPharma announced that their lead candidate Obexelimab crushed the primary endpoint in the Phase 2 MoonStone trial for Relapsing Multiple Sclerosis. This was presented at the ACTRIMS Forum in San Diego back in February, and honestly the data looks solid.

Here's what got my attention: the drug showed a 95% relative reduction in new gadolinium-enhancing T1 lesions compared to placebo over the 8 to 12 week window. That's not a marginal improvement - that's near-complete suppression of inflammation markers. Out of the obexelimab-treated patients, 97.2% stayed free of T1 lesions during that period. Meanwhile, the placebo group had 19 new lesions while the treatment group only had 2. Pretty stark difference.

What's interesting is the durability aspect. They followed patients through week 24, and the suppression held. The reduction in serum Neurofilament Light, which is a biomarker for neurodegeneration, dropped 40% by week 24. EDSS scores stayed stable too, meaning physical disability was controlled. No new safety signals popped up either, which is always good to see in MS trials.

The MoonStone trial was pretty straightforward - 116 patients randomized 2:1 to either 250mg obexelimab or placebo via weekly subcutaneous injection. After the 12-week blinded phase, placebo patients crossed over to active treatment and everyone could continue into a 52-week extension. That's a solid trial design.

What's making this relevant for the market is that Zenas isn't just betting on MS. They've got Obexelimab in eight clinical trials across different indications. The Phase 3 INDIGO trial for IgG4-Related Disease already hit both primary and secondary endpoints. They're planning to file a BLA with the FDA in Q2 2026 and an MAA with the EMA in the second half. They're also running a Phase 2 trial in Systemic Lupus Erythematosus with topline results expected in Q4 2026.

On the funding side, Zenas reported $301.6 million in cash and investments as of September 2025, plus $120 million from a private equity round in October. They say that's enough to fund operations into Q4 2026, though they'll need more capital beyond that. Stock-wise, ZBIO has been trading between $6.11 and $44.60 since April 2025. It closed Monday at $22.48, up 3.12%, but pulled back 2.67% in overnight trading to $21.88.

The MoonStone results are definitely noteworthy for anyone tracking biotech catalysts. This is exactly the kind of clinical validation that could move the needle for a company sitting on multiple shots on goal across different diseases.